Zobrazeno 1 - 10
of 124
pro vyhledávání: '"Carol Aghajanian"'
Autor:
Linda R. Duska, Roisin E. O'Cearbhaill, Sarah W. Gordon, Alice P. Chen, Joan L. Walker, Carol Aghajanian, Saketh R. Guntupalli, Paula M. Fracasso, Cara Mathews, Katherine M. Bell-McGuinn, J. Gillen, Deborah K. Armstrong, Russell J. Schilder, Austin Miller, John L. Hays, Kathleen N. Moore, Heidi J. Gray, Andrea R. Hagemann
Publikováno v:
Gynecol Oncol
Objective To evaluate how women with epithelial ovarian cancer (EOC), dichotomized by BRCA status, tolerate intravenous (IV) or intraperitoneal (IP) chemotherapy given with veliparib and bevacizumab (bev) on a GOG phase I study (GOG 9923, NCT00989651
Autor:
Cara Mathews, Xun Clare Zhou, Peter G. Rose, Virginia L. Filiaci, Michael T. McHale, Amanda Jackson, Heather A. Lankes, Debra L. Richardson, Douglas A. Levine, Carol Aghajanian, Angeles Alvarez Secord, Krishnansu S. Tewari, Kimberly K. Leslie, Casey Cosgrove, Katherine M. Moxley, Summer B. Dewdney, Yovanni Casablanca, David G. Mutch, Eric J. Devor, Megan E McDonald, Kristina W. Thiel, Adrianne R. Mallen
Publikováno v:
Gynecol Oncol
Background Successfully combining targeted agents with chemotherapy is an important future goal for cancer therapy. However, an improvement in patient outcomes requires an enhanced understanding of the tumor biomarkers that predict for drug sensitivi
Autor:
Carol Aghajanian, Paul DiSilvestro, Robert L. Coleman, Bradley J. Monk, Matthew A. Powell, Michael W. Sill, Stephen C. Rubin, Robert S. Mannel, John H. Farley, Leslie M. Randall, Krishnansu S. Tewari
Publikováno v:
Gynecol Oncol
Objective To explore the relationship between tumor size and response to combined anti-vascular targeted therapy using the anti-angiogenesis inhibitor, bevacizumab, and the tubulin-binding vascular disrupting agent, fosbretabulin. Methods An explorat
Autor:
Karen Cadoo, Jason A. Konner, Roisin E. O'Cearbhaill, Rachel N. Grisham, Debra M. Sarasohn, Jacqueline Gallagher, Melissa Henson, William P. Tew, Nicole N. Boucicaut, Carol Aghajanian, Vicky Makker, Dmitriy Zamarin, Qin Zhou, Sara Kravetz, Paul Sabbatini, Alexia Iasonos
Publikováno v:
Gynecol Oncol
Objective We assessed the safety and maximum tolerated dose (MTD) of the poly ADP-ribose polymerase (PARP) inhibitor olaparib with intravenous (IV)/intraperitoneal (IP) cisplatin/paclitaxel and IV bevacizumab, followed by olaparib and bevacizumab mai
Autor:
Jason A. Konner, Ying L Liu, Vivian N. Emengo, Roisin E. O'Cearbhaill, Carol Aghajanian, Dmitriy Zamarin, Alexia Iasonos, Claire F. Friedman, Qin Zhou
Publikováno v:
Gynecol Oncol
OBJECTIVES: Immune checkpoint inhibitors (ICIs) have modest activity in ovarian cancer (OC), yet little is known about their effects on subsequent treatment. Preclinical studies suggest immunotherapy may enhance response to chemotherapy. We sought to
Autor:
Barbara M. Norquist, Danielle Enserro, Bradley J. Monk, Michael A. Bookman, Matthew P. Boente, John K. Chan, Robert L. Coleman, Robert A. Burger, Michael J. Birrer, Philip J. DiSaia, Thomas J. Herzog, Krishnansu S. Tewari, Benjamin E. Greer, Helen Q. Huang, Howard D. Homesley, Elizabeth M. Swisher, Carlos Bais, Mark F. Brady, Leslie M. Randall, C. Ye, Larry J. Copeland, Sharon X. Liang, J. Stuart Ferriss, Carol Aghajanian, Robert S. Mannel, Gini F. Fleming, Jeffrey M. Fowler
Publikováno v:
J Clin Oncol
PURPOSE We report the final, protocol-specified analysis of overall survival (OS) in GOG-0218, a phase III, randomized trial of bevacizumab in women with newly diagnosed ovarian, fallopian tube, or primary peritoneal carcinoma. METHODS A total of 1,8
Autor:
Alexia Iasonos, Roisin E. O'Cearbhaill, Qin Zhou, Ekaterina Doubrovina, David R. Spriggs, Carol Aghajanian, Sara Kravetz, Richard J. O'Reilly, Paul Sabbatini, Chrisann Kyi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundThis phase I dose escalation trial evaluated the feasibility of production, safety, maximum tolerated dose, and preliminary efficacy of autologous T cells sensitized with peptides encoding Wilms’ tumor protein 1 (WT1) administered alone o
Autor:
Giovanni Scambia, Andrew R Clamp, Ana Oaknin, Susana Banerjee, Terri Cameron, David M. O'Malley, Nicoletta Colombo, Robert L. Coleman, Jonathan A. Ledermann, Andrew Dean, Amit M. Oza, Domenica Lorusso, Jeffrey C. Goh, Margarita Amenedo Gancedo, Jesús García-Donas, Johanne I Weberpals, Robert W. Holloway, Sandra Goble, Alexandra Leary, Elizabeth M. Swisher, Deborah K. Armstrong, Peter C.C. Fong, Carol Aghajanian
Publikováno v:
Int J Gynecol Cancer
IntroductionIn ARIEL3 (NCT01968213), the poly(adenosine diphosphate-ribose) polymerase inhibitor rucaparib significantly improved progression-free survival versus placebo regardless of biomarker status when used as maintenance treatment for recurrent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c04ef495b5cab90306c251bb18fd5030
https://europepmc.org/articles/PMC9445915/
https://europepmc.org/articles/PMC9445915/
Autor:
Robert S. Mannel, Robert A. Burger, David S. Alberts, Daniel S. Kapp, Robert F. Ozols, Michael A. Bookman, Maurie Markman, Bradley J. Monk, James J. Java, John K. Chan, Robert C. Young, Deborah K. Armstrong, Jeffrey G. Bell, Carol Aghajanian, Katherine Fuh, William P. McGuire
Publikováno v:
Gynecologic oncology, vol 154, iss 2
PurposeTo compare patient/tumor characteristics and outcomes of Asians to Caucasian patients with epithelial ovarian cancer.MethodsAncillary data were pooled and analyzed from ten prospective randomized front-line Gynecologic Oncology Group clinical
Autor:
Angeles Alvarez Secord, Albert J. Bonebrake, Ashley Stuckey, Michael W. Sill, Laurel W. Rice, Krishnansu S. Tewari, Joan L. Walker, Carol Aghajanian, Jeanne M. Schilder, William P. Tew
Publikováno v:
Gynecologic Oncology. 151:257-263
PURPOSE: Bevacizumab (BV) monotherapy leads to compensatory upregulation of multiple signaling pathways, resulting in mTOR activation. We evaluated combining BV and everolimus (EV), an mTOR kinase inhibitor, to circumvent BV-resistance in women with